

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Guillermo MOR

Application Serial No.: not yet assigned

Application Filed: concurrently

For: APOPTOSIS-BASED EVALUATION OF CHEMOSENSITIVITY IN CANCER  
PATIENTS

---

U.S. Patent and Trademark Office  
Customer Service Window  
**Mail Stop New Application**  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §1.97(b)**

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

- ☒ Pursuant to 37 C.F.R. §1.98, a copy of each non-US patent document cited in the attached Form PTO/SB/08 is enclosed.
- ☐ No copies of the publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. \_\_\_\_\_ to which the above-identified application claims priority under 35 U.S.C. §120.
- ☐ No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98.
- ☐ Publication(s) \_\_\_ listed on the attached Form PTO/SB/08 were cited in a foreign search or examination report corresponding to \_\_\_ application serial no. \_\_\_ and mailed on \_\_\_.
- ☐ Enclosed is a copy of a non-English publication(s) \_\_\_\_\_. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).
- ☐ Enclosed is a copy of a non-English publication(s) \_\_\_\_\_. English language publication \_\_\_ (copy enclosed) claims priority from this non-English publication.

- ☐ Enclosed is an explanation of non-English publication(s) \_\_\_ for which an English translation is not available.
- ☐ Enclosed is an English translation of non-English publication(s) cited in the attached Form PTO/SB/08.
- ☐ Enclosed is a copy of pending patent Application Serial No. \_\_\_.

This Information Disclosure Statement is filed within any one of the following time periods:


- ☐ within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);
- ☒ within three months from the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in this international application;
- ☐ before the mailing date of a first office action on the merits; or
- ☐ before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08 to the undersigned.

Dated: May 22, 2006

COOLEY GODWARD LLP  
ATTN: Patent Group  
The Bowen Building  
875 15<sup>th</sup> Street NW, Suite 800  
Washington, DC 20005-2221  
Tel: (202) 842-7800  
Fax: (202) 842-7899

Respectfully submitted,  
**COOLEY GODWARD LLP**

By:   
Heather M. Boussios  
Reg. No. 52,704

Please type a plus sign (+) inside this box → +

**1AP20 Rec'd PCT/PTO 22 MAY 2006**

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	not yet assigned <b>10/580170</b>
		Filing Date	concurrently
		First Named Inventor	Guillermo Mor
		Group Art Unit	not yet assigned
		Examiner Name	not yet assigned
Sheet	1 of 1	Attorney Docket Number	YALE-106/00US

OTHER – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/C.Y./	1	Ofir <i>et al.</i> , 2002, Taxol-Induced Apoptosis in Human SKOV3 Ovarian and MCF7 Breast Carcinoma Cells in Caspase-3 and Caspase-9 Independent, Cell Death and Differentiation, 9, 636-642.	
/C.Y./	2	Kolfshoten <i>et al.</i> , 2002, Time-Dependent Changes in Factors Involved in the Apoptosis Process in Human Ovarian Cancer Cells as a Response to Cisplatin, Gynecologic Oncology, 84, 404-412.	
/C.Y./	3	Saito <i>et al.</i> , 2004, Correlation Between Responsiveness of Neoadjuvant Chemotherapy and Apoptosis-Associated Proteins for Cervical Adenocarcinoma, Gynecologic Oncology, 92, 284-292.	

Examiner Signature <b>/Christopher Yaen/ (03/11/2009)</b>	Date Considered	<b>03/11/2009</b>
---	-----------------	-------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number (optional). <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*